Justia Consumer Law Opinion Summaries

Plaintiffs' son, who was allergic to dairy, tree nuts and fish, suffered an allergic reaction after eating a "vegan cupcake from Whole Foods. Plaintiffs filed negligence and strict liability claims against Whole Foods, based in part on Mother leaving her job to provide full-time care for her son. In response, Whole Foods argued that Plaintiffs' claims were preempted by the Food, Drug, and Cosmetic Act. The district court granted Whole Foods' motion and plaintiffs appealed.On appeal, the Fifth Circuit reversed, finding that Plainitffs' claims were not impliedly preempted because each of their tort claims is “a recognized state tort claim” rather than “a freestanding federal cause of action based on violation of FDA regulations. View "Spano v. Whole Foods, Inc." on Justia Law

The Food and Drug Administration (“FDA”) approved mifepristone to be marketed with the brand name Mifeprex under Subpart H (the “2000 Approval”). In January 2023, FDA approved a modified REMS for mifepristone, lifting the in-person dispensing requirement.  Plaintiffs (physicians and physician organizations) filed a suit against FDA, HHS, and a several agency heads in the official capacities. Plaintiffs challenged FDA’s 2000 Approval of the drug and also requested multiple grounds of alternative relief for FDA’s subsequent actions. Plaintiffs moved for a preliminary injunction ordering FDA to withdraw or suspend (1) FDA’s 2000 Approval and 2019 Generic Approval, (2) FDA’s 2016 Major REMS Changes, and (3) FDA’s 2021 Mail-Order Decision and its 2021 Petition Denial of the 2019 Citizen Petition. The district court entered an order staying the effective date of the 2000 Approval and each of the subsequent challenged actions.   The Fifth Circuit granted Defendants’ motions for a stay pending appeal. The court wrote that at this preliminary stage, and based on the court’s necessarily abbreviated review, it appears that the statute of limitations bars Plaintiffs’ challenges to the Food and Drug Administration’s approval of mifepristone in 2000. However, Plaintiffs brought a series of alternative arguments regarding FDA’s actions in 2016 and subsequent years. And the district court emphasized that its order separately applied to prohibit FDA’s actions in and after 2016 in accordance with Plaintiffs’ alternative arguments. As to those alternative arguments, Plaintiffs’ claims are timely. Defendants have not shown that Plaintiffs are unlikely to succeed on the merits of their timely challenges. For that reason, Defendants’ motions for a stay pending appeal are denied in part. View "Alliance Hippocratic Medicine v. FDA" on Justia Law

Plaintiff was on active duty with the United States Army. He bought a car from Select Cars of Thornburg in Fredericksburg, Virginia, and financed his purchase with a loan from United Auto Credit Corporation. The loan financed not only the car’s cost but also the cost of Guaranteed Asset Protection. Guaranteed Asset Protection is like extra insurance, covering any amount still due on the car loan after auto insurance is paid out if the car is totaled or stolen. Plaintiff’s claims arise from this single loan. This loan, Plaintiff alleged, violated the Military Lending Act because the loan agreement mandated arbitration and failed to disclose certain information. The district court dismissed the case, holding that the loan was not covered by the Act at all.   The Fourth Circuit affirmed. The court explained that a statutory provision must be given the ordinary meaning it had when it was enacted. Relevant dictionaries, carefully considered, sometimes shed light on that ordinary meaning. Yet here, dueling dictionaries provide more than one linguistically permissible meaning.  But by examining the relevant phrase in its statutory context. This context shows that while “the express purpose” can be used in different senses, it is best read in Section 987(i)(6) to mean the specific purpose. This loan was offered for the specific purpose of financing Plaintiff’s car purchase. And that satisfies Section 987(i)(6)’s relevant condition and the Act is inapplicable. View "Jerry Davidson v. United Auto Credit Corporation" on Justia Law

Louisiana passed the Truth in Labeling of Food Products Act (the “Act”) to “protect consumers from misleading and false labeling of food products that are edible by humans.” The Act bars, among other things, the intentional “misbranding or misrepresenting of any food product as an agricultural product” through several different labeling practices. Turtle Island Foods, S.P.C. (d/b/a Tofurky), markets and sells its products in Louisiana. Tofurky believes it operates under a constant threat of enforcement. Tofurky sued Louisiana’s Commissioner of Agriculture and Forestry, seeking declaratory and injunctive relief. The parties filed cross-motions for summary judgment, and the district court sided with Tofurky. It held that Tofurky had standing to challenge the Act and that the statute was an unconstitutional restriction on Tofurky’s right to free speech. The State appealed.   The Fifth Circuit reversed. The court explained that nothing in the statute’s language requires the State to enforce its punitive provisions on a company that sells its products in a way that just so happens to confuse a consumer. The State’s construction limits the Act’s scope to representations by companies that actually intend consumers to be misled about whether a product is an “agricultural product” when it is not. This interpretation is not contradictory to the Act, and the court thus accepted it for the present purposes of evaluating Tofurky’s facial challenge. The district court erred in ignoring the State’s limiting construction and in implementing its own interpretation of the Act. View "Turtle Island Foods v. Strain" on Justia Law

This is an appeal from a district court order approving a class-action settlement that purports to provide injunctive relief and up to $8 million in monetary relief to a class of individuals (the “Class”) who purchased one or more “brain performance supplements” manufactured and sold by Defendants Reckitt Benckiser LLC and RB Health (US) LLC (together, “RB”) under the brand name “Neuriva.” Five Plaintiffs (together, the “Named Plaintiffs”) who had previously purchased Neuriva brought a putative class action, alleging that RB used false and misleading statements to give consumers the impression that Neuriva and its “active ingredients” had been clinically tested and proven to improve brain function. The parties promptly agreed to a global settlement (the “Settlement” or “Settlement Agreement”) that sought to resolve the claims of all Plaintiffs and absent Class members. The current appeal involves one unnamed Class member, an attorney and frequent class-action objector, who objected in district court and subsequently appealed the district court’s approval order.   The Eleventh Circuit vacated the district court’s order and remanded. The court concluded that the Named Plaintiffs lack standing to pursue their claims for injunctive relief. The court explained that Plaintiffs seeking injunctive relief must establish that they are likely to suffer an injury that is “actual or imminent,” not “conjectural or hypothetical.” But none of the Named Plaintiffs allege that they plan to purchase any of the Neuriva Products again. The district court, therefore, lacked jurisdiction to award injunctive relief to the Named Plaintiffs or absent Class members, and its approval of the Settlement Agreement was an abuse of discretion. View "David Williams, et al v. Reckitt Benckiser LLC, et al" on Justia Law

Plaintiffs Oscar and Audrey Madrigal sued defendant Hyundai Motor America (Hyundai) under California’s automobile lemon law. Early in the case, Hyundai made two offers to compromise under Code of Civil Procedure section 998, both of which were rejected. After a jury was sworn in, plaintiffs settled with Hyundai for a principal amount that was less than Hyundai’s second section 998 offer. The parties elected to leave the issue of costs and attorney fees for the trial court to decide upon motion. Under the settlement agreement, once the issue of costs and attorney fees was resolved and payment was made by Hyundai, plaintiffs would dismiss their complaint with prejudice. The issue this case presented for the Court of Appeal's review centered on whether section 998’s cost-shifting penalty provisions apply when an offer to compromise is rejected and the case ends in settlement. Under the facts of this case, the Court held that it did and therefore reversed the order of the trial court. View "Madrigal v. Hyundai Motor America" on Justia Law

Weichsel's Chase credit card member agreement discloses an “Annual Membership Fee” to be added to his billing statement and that Weichsel may request an additional card for an authorized user. A “Rates and Fees Table” discloses the annual membership fee as $450 plus $75 for each additional card. Weichsel included one additional user. Weichsel alleges that his December 2019 billing statement included a renewal notice, stating that Weichsel’s annual $525.00 membership fee would be billed on 02/01/2020, how the fee would be charged, and how Weichsel could avoid it. The notice did not specify the breakdown: $450 for the primary cardholder and $75 for the additional user. The fee appeared as separate items on Weichsel’s February 2020 billing statement: a $450 charge and another for $75. Weichsel paid $525 but claims that “[h]ad [he] been aware” he could retain his credit card for $450, he would have paid only that amount. Weichsel filed a putative class action, alleging that Chase’s failure to itemize each component of the renewal fee in the December 2019 renewal notice violated the Truth in Lending Act (TILA), 15 U.S.C. 1601, and Regulation Z.The Third Circuit affirmed the dismissal of the suit. Weichsel had standing; he suffered an economic injury based on his assertion that he would not have paid the full $525 if he had known it included the additional card fee. However, neither TILA nor Regulation Z expressly mandates disclosure of each individual component of the total annual fee in a renewal notice. Regulation Z requires itemization of fees on other disclosures but lacks such a requirement for renewal notices. View "Weichsel v. JP Morgan Chase Bank NA" on Justia Law

Ranger purchased a new Hyundai vehicle in 2018. Ranger experienced some problems with the vehicle, and it had to be repeatedly repaired. His lawyer wrote a demand letter to Hyundai, seeking a refund of the purchase price “along with all interest paid on the finance note as well as attorney fees and incidental and consequential damages.” Hyundai offered to repurchase the vehicle “pursuant to the applicable statutes” and offered to pay some of the attorney’s fees. Ranger refused the offer on the basis that Hyundai failed to sufficiently reimburse him for his pre-litigation attorney’s fees.Ranger then sued under the Lemon Law, Code 59.1-207.10. The circuit court dismissed the suit. The Supreme Court of Virginia affirmed. To satisfy the refund requirements under Virginia’s Lemon Law, a manufacturer is not required to pay pre-litigation attorney’s fees. The manufacturer’s refund satisfied the requirements of the Lemon Law. View "Ranger v. Hyundai Motor America" on Justia Law

Acuity operates a website that connects people looking to buy or sell homes with a local real estate agent. Acuity’s services are free to home buyers and sellers but realtors pay a fee for referrals. The real-estate broker that employed Lewis, a real estate agent, signed up to receive Acuity’s referrals. The broker required its agents (including Lewis) to pay Acuity’s fee out of their commissions from home sales. Lewis sued, alleging that Acuity makes false claims to home buyers and sellers on its website and that this false advertising violates the Lanham Act, 15 U.S.C. 1125(a)(1)(B).The Sixth Circuit affirmed the dismissal of the suit. The Lanham Act provides a cause of action only for businesses that suffer commercial injuries (such as lost product sales) from the challenged false advertising. The Act does not provide a cause of action for customers who suffer consumer injuries (such as the cost of a defective product) from false advertising. Lewis alleges that type of consumer harm as his injury from Acuity’s allegedly false advertising: He seeks to recover the referral fee (that is, the price) he paid for Acuity’s services. View "Lewis v. Acuity Real Estate Services, LLC" on Justia Law

The Investigative Consumer Reporting Agencies Act (ICRAA, Civil Code, 1786) mandates certain disclosures for investigative consumer reports, which are often used by landlords to make decisions regarding consumers who apply for housing. ICRAA requires the adoption of “reasonable procedures” for providing consumer information “in a manner which is fair and equitable to the consumer," concerning the confidentiality, accuracy, relevancy, and proper utilization of their information. Any investigative consumer reporting agency or user of information that fails to comply with the requirements is liable to the affected consumer for any actual damages or $10,000, whichever sum is greater. Courts of appeal disagreed about the constitutionality and enforceability of ICRAA.In 2018, the California Supreme Court upheld the constitutional validity of ICRAA. Bernuy had filed one of 27 consolidated actions seeking damages against BPMC for its commission of ICRAA violations in 2017. Bernuy’s action was designated a “bellwether” case for adjudicating certain issues. The court of appeal held that the California Supreme Court’s 2018 decision did not constitute a subsequent change in the law that relieved BPMC of liability for its ICRAA violations. However, certain plaintiffs’ ICRAA claims are time-barred under the applicable two-year statute of limitations. The limitations period was not tolled by the pendency of a putative class action. View "Bernuy v. Bridge Property Management Co." on Justia Law